Medscape4d
FDA Approves Third Tocilizumab Biosimilar
The biosimilar will be available in both subcutaneous and intravenous formulations and has nearly all the same indications as ...
The American Journal of Managed Care7d
FDA Approves Celltrion’s Tocilizumab-anoh, Biosimilar to Actemra
Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, ...
Hosted on MSN3d
Celltrion’s Avtozma receives FDA approval for multiple conditions
The FDA's approval is grounded in an evidence totality and comprehensive data package, which includes outcomes from a study.
Medscape5d
Tocilizumab: The First Interleukin-6-Receptor Inhibitor
Purpose: The pharmacology, pharmacokinetics, clinical efficacy, safety, and role of tocilizumab in rheumatoid arthritis (RA) are reviewed. Summary: Tocilizumab is a novel monoclonal antibody that ...
Healio6d
FDA approves third Actemra biosimilar; second available in intravenous, subcutaneous forms
The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.
centerforbiosimilars7d
FDA Approves Celltrion's Avtozma as Third Tocilizumab Biosimilar
The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.
Pharmabiz6d
Celltrion’s Avtozma, a biosimilar to Actemra receives US FDA approval to treat RA, GCA, pJIA, sJIA and Covid-19
Jersey City, New Jersey Saturday, February 1, 2025, 16:00 Hrs [IST] ...
infectiousdiseaseadvisor.com2d
FDA Approves Tocilizumab Biosimilar Avtozma
The FDA has approved Avtozma® (tocilizumab-anoh), a biosimilar to Actemra®, in both intravenous and subcutaneous formulations.
Managed Healthcare Executive4d
FDA Approves Third Biosimilar of Actemra
The new biosimilar, Celltrion’s Avtozma, was approved in both IV and subcutaneous forms to treat inflammatory conditions such as arthritis.
Contract Pharma7d
FDA Approves Celltrion’s Biosimilar to ACTEMRA
The U.S. Food and Drug Administration (FDA) has approved Celltrion’s AVTOZMA (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and subcutaneous (SC) formulation as a biosimilar to ACTEMRA.
PipelineReview.com7d
U.S. FDA approves Celltrion’s AVTOZMA® (tocilizumab-anoh), a biosimilar to ACTEMRA®
JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...
Monthly Prescribing Reference7d
FDA Approves Tocilizumab Biosimilar Avtozma
Findings showed tocilizumab-anoh had comparable efficacy, pharmacokinetics, safety, and immunogenicity with Actemra. The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab ...